Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd. has seen notable stock performance, with a 6.48% increase on August 21, 2026, and a 21.23% rise over the past week. The company reported a robust annual return of 21.6% and a market capitalization of CNY 20,721 million, reflecting strong financial metrics.

Walvax Biotechnology Co., Ltd. has experienced notable stock performance, rising significantly today and showing a strong monthly gain. Despite facing long-term growth challenges with declining net sales, recent financial metrics indicate improvements, including a positive return on capital employed and a substantial pre-tax profit for the latest quarter.

Walvax Biotechnology Co., Ltd. has demonstrated strong stock performance today, significantly outperforming the China Shanghai Composite. Over the past year, the company has achieved a notable increase, while facing challenges in the longer term. Key financial metrics indicate an attractive valuation and a positive quarterly profit report.

Walvax Biotechnology Co., Ltd. faced a notable decline in its stock price on July 17, 2026, reaching an intraday low. Despite recent challenges, the company has shown resilience with a year-to-date performance significantly outperforming the broader market, maintaining a market capitalization of CNY 17,496 million.

Walvax Biotechnology Co., Ltd. has experienced notable stock performance, rising significantly today and over the past month, outperforming the Shanghai Composite index. Despite challenges in long-term growth metrics, the company reported positive recent results, including a return on capital employed of 3.39% and a market capitalization of CNY 17,496 million.

Walvax Biotechnology Co., Ltd. has seen a notable rise in stock performance, achieving a significant intraday high. Year-to-date, the company has outperformed the China Shanghai Composite, despite a decline in net sales over five years. Recent quarterly results show impressive net profit growth and strong financial stability indicators.

Walvax Biotechnology Co., Ltd. has experienced notable stock activity, rising significantly today while the broader market declined. Despite a challenging month, the company has shown strong year-to-date performance and impressive quarterly net profit growth. Key financial metrics suggest an attractive valuation, indicating a potential shift in momentum.

Walvax Biotechnology Co., Ltd. has experienced notable stock activity, outperforming the China Shanghai Composite in recent weeks. While facing long-term challenges with declining net sales and operating profit, the company reported substantial quarterly net profit growth, highlighting a potential turnaround in profitability and an attractive valuation for investors.

Walvax Biotechnology Co., Ltd. saw a significant stock decline today, contrasting with the minor decrease in the China Shanghai Composite. Despite recent challenges, the company reported a substantial net profit increase and has shown resilience over the past year, although long-term performance reveals considerable declines.

Walvax Biotechnology Co., Ltd. saw a significant stock decline, reaching an intraday low amid a challenging trading environment. Over the past month, the stock has dropped considerably, despite reporting substantial net profit growth. The company's market capitalization is CNY 17,496 million, with a low return on equity and a high P/E ratio.

Walvax Biotechnology Co., Ltd. saw a significant stock decline today, coinciding with a broader market downturn. Despite a strong annual performance, the company has faced substantial long-term challenges. Financial metrics reveal mixed results, including impressive net profit growth but a notable decline in operating profit, alongside a high dividend yield and modest return on equity.

Walvax Biotechnology Co., Ltd. has shown significant growth, with a 20.45% increase over the past month and a year-to-date return of 31.16%. Despite challenges in long-term growth, the company reported a remarkable net profit growth of 4082.41% in its latest quarterly results, highlighting a turnaround in performance.

Walvax Biotechnology Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market's downturn. The company has struggled with consistent negative financial results over the past seven quarters, alongside modest annual sales growth and significant long-term stock depreciation, raising concerns about its profitability and market position.

Walvax Biotechnology Co., Ltd. faced a significant decline in its stock today, contrasting with the broader market's performance. The company reported a 17.19% drop in net sales and a net profit loss of CNY 43.3 million, continuing a trend of negative results over seven quarters. Its three-year stock return stands at -70.37%.